Index/Topics/Lecanemab/BAN2401 Trials

Lecanemab/BAN2401 Trials

Phase 2/3 antibody programs using Bayesian designs and specifying clinical composites or ADAS-Cog-type measures as primary endpoints to quantify disease-modifying effects on cognition and function.